medigraphic.com

2007, Número S4

<< Anterior Siguiente >>

Arch Cardiol Mex 2007; 77 (S4)


Atrial fibrillation: the relation between heart and brain

Plesiewicz I, Kuilenburg J, Gheorghe AMP

Idioma: Ingles.
Referencias bibliográficas: 33
Paginas: 111-115
Archivo PDF: 130.11 Kb.


FRAGMENTO

Sin resumen


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Kannel WB, Wolf PA, Benjamin EJ, Levy D: Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol 1998; 82: 2N-9N.

  2. Go AS, Hylek EM, Philips KA, Chang Y, Henault LE, Selby JV, Singer DE: Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. JAMA 2001; 285: 2370-2375.

  3. Wattigney WA, Mensah GA, Croft JB: Increasing trends in hospitalization for atrial fibrillation in the United States., 1985 through 1998: implications for primary prevention. Circulation 2003; 108: 711-716.

  4. Movahed M, Hashemzadeh M, Mazen JM: Diabetes mellitus is a strong, independent risk for atrial fibrillation in addition to other cardiovascular disease. Int J Cardiol 2005; 105: 315-318.

  5. Fuster V, et al: Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines. Circulation 2006; 114(7): 257-354.

  6. Hart RG, Benavente O, McBride R: Antithrombotic therapy to prevent stroke in atrial fibrillation: a meta-analysis. Ann Intern Med 1999; 131: 492-501.

  7. Chang Yj, Ryu SJ, Lin SK: Carotid artery stenosis in ischemic stroke patients with nonvalvular atrial fibrillation. Cerebrovasc Dis 2002; 13: 16-20.

  8. Ross R: Atherosclerosis: an inflammatory disease. N Engl J Med 1999; 340: 115-126.

  9. Libby P: Inflammation in atherosclerosis. Nature 2002; 420: 868-874.

  10. Libby P, Ridker P, Maseri A: Inflammation and atherosclerosis. Circulation 2002; 105: 1135-1143.

  11. Boos CJ, Anderson RA, Lip GYH: Is atrial fibrillation an inflammatory disorder? Eur Heart J 2006; 27: 136-149.

  12. Patti G, Chello M, Candura D: Randomized trial of atorvastatin for reduction of Postoperative Atrial Fibrillation in patients undergoing cardiac surgery. Results of the ARMYDA-3. Circulation 2006; 114: 1455-1461.

  13. Young-Xu Y, Jabbour S, Goldberg R: Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease. Am J Cardiol 2003; 92: 1379-1383.

  14. Weng X, Cloutier G, Beaulieu R, Roederer GO: Influence of acute-phase proteins on erythrocyte aggregation. Am J Physiol 1996; 271: H2346-2352.

  15. Devereux RB, Drayer JIM, Chien S: Whole blood viscosity as a determinant of cardiac hypertrophy in systemic hypertension. Am J Cardiol 1984; 54: 592-596.

  16. Goldsmith HL, Turitto VT: Rheological aspects of thrombosis and haemostasis: Basic principles and applications. Thromb and Haemost 1986; 55: 415-435.

  17. Koenig W, Ernst E: The possible role of hemorheology in atherothrombogenesis. Review Article. Atherosclerosis 1992; 94: 93-107.

  18. Chien S, Usami S, Dellenback RJ, Gregersen MI: Blood viscosity: influence of erythrocyte aggregation. Science 1967; 157: 829-831.

  19. Schmid-Schonbein H, Gaethgens P, Hirsch H: On the shear rate dependence of red cell aggregation in vitro. J Clin Invest 1968; 47: 1447-1454.

  20. Task Force American Heart Association. From vulnerable plaque to vulnerable patient. Circulation 2003; 108: 1664-1698.

  21. Lefebvre C, Deplanque D, Touze E: Prestroke dementia in patients with atrial fibrillation. Frequency and associated factors. J Neurol 2005; 252: 1504-1509.

  22. De Leeuw FE, de Groot JC, Oudkerk M: Atrial fibrillation and the risk of cerebral white matter lesions. Neurology 2000; 54(9): 1795-1801.

  23. EAFT Study Group. Silent brain infarction in nonrheumatic atrial fibrillation. European Atrial Fibrillation Trial. Neurology 1996; 46: 159-165.

  24. Stanley T, Mackensen GB, Grocott H: The impact of postoperative atrial fibrillation on neurocognitive outcome after coronary artery bypass surgery. Anesth Analg 2002; 94: 290-295.

  25. Grotta J, Ackerman R, Correja, Fallick G, Chang J: Whole blood viscosity parameters and cerebral blood flow. Stroke 1982; 13: 296-302.

  26. Ackerman RH: Cerebral blood flow and neurological change in chronic heart failure. Stroke 2001; 32: 2462-4.

  27. Black IW, Chesterman CN, Hopkins AP, Lee LC, Chong BH, Walsh WF: Hematologic correlates of left atrial spontaneous echo contrast and thromboembolism in nonvalvular atrial fibrillation. J Am Coll Cardiol 1993; 21: 451-457.

  28. Sigel B, Machi J, Beitler JC, Justin JR: Red cell aggregation as a cause of blood-flow echogenicity. Radiology 1983; 148: 799-802.

  29. Ito T, Suwa M, Nakamura T, Miyazaki S, Hirota Y, Kawamura K: Influence of Warfarin therapy on left atrial spontaneous echo contrast in nonvalvular atrial fibrillation. Am J Cardiol 1999; 84:857-9.

  30. Bernick C, Katz R, Smith NL: Statins and cognitive function in the elderly: the Cardiovascular Health Study. Neurology 2005; 8: 1388-1394.

  31. Hagens VE, Ranchor AV, van Sonderen E: Effect of rate or rhythm control on quality of life in persistent atrial fibrillation. Results from the Rate Control Versus Electrical Cardioversion (RACE) Study. J Am Coll Cardiol 2004; 43(2): 241-247.

  32. Wyse DG, Waldo AL, DiMarco: A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002; 347 (23):1825-1833.

  33. Lozano HF, Conde CA, Lamas GA: Treatment and prevention of atrial fibrillation with non-antiarrhythmic pharmacologic therapy. Heart Rhythm 2005; 2(9): 1000-1007. Review.




2020     |     www.medigraphic.com